GLP-1 receptor agonists (such as semaglutide and tirzepatide) and revisional bariatric surgery are both options sometimes discussed for patients with regain or inadequate loss. They are not equivalent and not mutually exclusive.
Mechanism
GLP-1 medications act on appetite, satiety, and metabolic pathways. Revisional surgery changes anatomy and the hormonal milieu through the GI tract.
Evidence and durability
GLP-1 medications produce meaningful weight loss for many patients while the medication is continued; regain after discontinuation is common in trial data. Revisional surgery is studied across multiple procedure types and produces durable anatomic changes, with outcomes that depend on patient and procedure factors.
Risks
Both options have risks. Medications can cause GI side effects and other adverse events. Revisional surgery carries perioperative risk that is typically different from primary surgery.
Combined use
In some patients, medical therapy and surgical revision may be discussed together rather than as alternatives. Individual evaluation is required.